Breast Cancer News Roundup: June 2026

June was a dense month for breast cancer research and regulation, anchored by the ASCO 2026 Annual Meeting, three new FDA actions, and fresh debate over screening guidelines and AI-driven detection. Here's a rundown of what mattered.

ASCO 2026: New Data Across Every Subtype

The American Society of Clinical Oncology's annual meeting delivered a packed breast cancer program. Highlights spanned early-stage, HER2-positive, hormone receptor-positive, and triple-negative disease:

• Chemo de-escalation in early ER+ disease. The phase 3 OPTIMA trial used the Prosigna PAM50 genomic assay to identify ER-positive, HER2-negative patients who could safely skip chemotherapy. Patients with a recurrence-risk score of 60 or below did just as well on endocrine therapy alone, and in women on ovarian suppression, most of chemo's apparent benefit turned out to be attributable to its endocrine effects.
• Long-term TNBC immunotherapy data hold up. Seven-year follow-up from KEYNOTE-522 showed that neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, improved both distant disease-free survival and overall survival in high-risk, early-stage triple-negative breast cancer (TNBC).
• HER2-positive de-escalation. The phase 2 IRIS-A trial explored dropping IV chemotherapy from adjuvant therapy in stage 1A, HER2-positive disease—part of a broader theme this year of asking which patients can be treated with less.
• Metastatic TNBC: ADCs gain ground. The phase 3 PANKU-Breast02 trial tested izalontamab brengitecan (iza-bren), an EGFR/HER3-targeting antibody-drug conjugate, against chemotherapy in metastatic TNBC. The interim analysis showed progression-free survival climbing from 3 to 9 months and overall survival from 12 to 16 months. Separately, updated TROPION-Breast02 data showed datopotamab deruxtecan (Dato-DXd; Datroway) delaying the need for subsequent therapy far longer than chemotherapy in immunotherapy-ineligible metastatic TNBC (a median of 10.9 vs. 5.6 months).
• ER+, PIK3CA-mutated disease. The phase 3 VIKTORIA-1 trial found that adding gedatolisib (a pan-PIK3CA/mTOR inhibitor) to palbociclib (Ibrance) and fulvestrant (Faslodex) produced an 11-month median progression-free survival vs 6 months for alpelisib (Piqray) plus fulvestrant, with notably less hypoglycemia, an adverse effect that has limited the alpelisib regimen.
• A mixed result for giredestrant. The phase 3 persevERA trial of the oral SERD giredestrant didn't hit statistical significance for its primary progression-free-survival end point vs letrozole plus palbociclib in metastatic ER+/HER2– disease, though it showed a numerical improvement. Researchers are still trying to square that with more positive earlier-stage results for the same drug. In a separate adjuvant-setting analysis, giredestrant did lower the risk of invasive disease recurrence compared with standard endocrine therapy, with fewer treatment discontinuations from joint pain than aromatase-inhibitor-heavy regimens.
• An unexpected GLP-1 finding. A real-world retrospective study of more than 148,000 women linked GLP-1 receptor agonist use (drugs like semaglutide) to a modest reduction in new HR+, HER2– breast cancer and meaningfully better overall survival among nondiabetic women with a BMI of 25 to 35. It's observational data, not a clinical trial, but it's generating interest as a possible secondary benefit of these drugs.
• ctDNA as a recurrence signal. Postsurgical circulating tumor DNA (ctDNA), measured by whole-genome sequencing, sharply separated patients by risk of distant recurrence (98% three-year disease-free survival for ctDNA-negative patients vs. 39.7% for ctDNA-positive). Notably, ctDNA status remained predictive even in statistical models where pathologic complete response did not, suggesting it may become a more reliable marker than tumor response itself.

FDA Actions

Several regulatory decisions landed in June, building on a string of approvals earlier in the spring:

• Palbociclib expanded to HER2+ disease (June 24). The FDA approved palbociclib in combination with trastuzumab (Herceptin), with or without pertuzumab (Perjeta), plus endocrine therapy, as maintenance treatment for HR+, HER2+ metastatic breast cancer following induction therapy. The approval was based on the PATINA trial and marks a first foray for this CDK4/6 inhibitor into HER2+ disease.
• Giredestrant fast-tracked. The FDA granted fast-track designation to the oral SERD giredestrant for early-stage ER+/HER2– breast cancer, after phase 3 data showed roughly 30% fewer invasive recurrences.
• Generic eribulin approved. A generic version of eribulin mesylate, used for pretreated metastatic breast cancer, was approved, which should help with cost and access.

This followed a busy May, when the FDA approved Dato-DXd for metastatic TNBC patients ineligible for immunotherapy, vepdegestrant (Veppanu)—the first-ever approved PROTAC protein degrader—for ESR1-mutated advanced ER+/HER2– disease, and 2 new uses of trastuzumab deruxtecan (T-DXD; Enhertu) before and after surgery for HER2+ early-stage breast cancer.

Looking ahead, gedatolisib has a PDUFA decision expected in mid-July for HR+, HER2–, PIK3CA-wild-type advanced breast cancer.

Screening Ruidance remains Contested

A new guidance statement from the American College of Physicians, paired with a Cochrane review from Trinity College Dublin and St. James's Hospital, has reopened debate over when average-risk women should start mammograms and how often. The ACP's update—covering supplemental MRI/ultrasound use, AI-assisted mammography, and starting age—diverges in places from the US Preventive Services Task Force's 2024 guidance (screening starting at 40, every 2 years, through age 74). Clinicians interviewed on the topic noted that genetic risk factors (BRCA1/2, PALB2, TP53, CHEK2, ATM mutations), family history, and lifestyle factors like obesity should all weigh into an individualized starting point, rather than a single age cutoff for everyone.

AI and Early Detection

Two notable studies pushed the AI-in-screening conversation forward:

• A Swedish study published in Radiology found that three commercially available AI mammography systems could retrospectively flag signs of breast cancer up to 6 years before diagnosis in some cases. Researchers estimated that about 20% of eventual breast cancer cases already showed AI-detectable mammographic signs roughly 6 years out, raising the possibility of tracking AI risk scores over time rather than just reading a single mammogram in isolation.
• Separately, researchers found that AI-derived image-based risk scores from screening mammograms change over time, and that the trajectory of those changes differs between women who go on to develop cancer and those who don't—another step toward dynamic, longitudinal risk assessment rather than a single snapshot read.

Disparities and Access

The Keck School of Medicine of USC and Novartis announced a new collaboration aimed at closing breast cancer screening and outcome gaps in underserved Los Angeles communities. The partnership cites a persistent and not-fully-explained pattern: Black women in the US have higher screening rates than white women, yet about 40% higher mortality, a gap linked to unequal access to timely, high-quality follow-up care. Native American and Hispanic women also face disproportionately later-stage diagnoses. The collaboration will focus on practical barriers of insurance, language, and transportation rather than screening rates alone.

In related lab research, scientists also reported new findings on how surrounding fat tissue may influence the way triple-negative breast cancer spreads, and a separate team identified immune markers that may help predict which patients are unlikely to benefit from chemotherapy, potentially sparing some from treatment that wouldn't help them.

The Bottom Line

June reinforced a few clear trends in breast cancer care: antibody-drug conjugates continue to move earlier into treatment lines, especially for TNBC; genomic and ctDNA testing are increasingly used to figure out who can safely get less treatment, not just who needs more; and the open questions remain very much unresolved even as the drug pipeline accelerates.

REFERENCES

ASCO 2026 Breast Cancer Highlights: Beyond the LBAs. Targeted Oncology. June 9, 2026. https://tinyurl.com/554k9z9y

US FDA. Oncology (Cancer)/Hematologic Malignancies Approval Notifications. https://tinyurl.com/nhr6pwky

Sakay, YN. 2026 breast cancer screening guidelines: Experts clarify when to start. Medical News Today, June 2, 2026. https://tinyurl.com/457t8wwc

Can AI Provide an Early Alert for Breast Cancer Before Diagnosis. The ASCO Post, June 17, 2026. https://tinyurl.com/44pffene

Fat tissue could explain triple negative breast cancer spread - and point to treatments. eCancer. June 24, 2026. https://tinyurl.com/yprka3y6